Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
General22 hours agoAFL round 13 live: North Melbourne vs West Coast, Carlton vs Essendon updates, scores and highlights
-
General21 hours agoKyle Chalmers says Brisbane 2032 Olympic Games is possible after contemplating retirement
-
Noosa News19 hours agoDaly Cherry-Evans set to be dropped as Maroons captain
-
Noosa News19 hours agoThe Story Bridge should serve as a warning – and an opportunity